# Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other

Source: https://onco.cc/trials/nct07468071/  
OnCo record `nct07468071` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JDQ443, Trametinib, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments is a phase 1/2 interventional study registered as NCT07468071 by Novartis Pharmaceuticals, with 40 participants planned, started 2026-06-08 and due to reach its primary completion in 2029-06-11. Interventions recorded: Opnurasib, TNO155, trametinib, cetuximab, tislelizumab. Conditions listed: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07468071
- Phase: 1/2
- Setting: KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07468071: https://clinicaltrials.gov/study/NCT07468071

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [JDQ443](https://onco.cc/drugs/jdq443/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [TNO155](https://onco.cc/drugs/tno155/), [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct07468071.json